Pionyr Immunotherapeutics

Pionyr Immunotherapeutics

Discovers and develops first-in-class biologic drugs that fine-tune natural immune responses to increase immune defenses for diseases such as cancer, or to dampen immune responses in autoimmune diseases.

HQ location
San Francisco, United States
Website
pionyrtx.com
Launch date
Employees
11-50 people
Enterprise value
$1.1—1.7b
https://twitter.com/pionyrimmunotxhttps://www.linkedin.com/company/pionyr-immunotherapeutics
    • Edit
loading funding rounds…
John G. Freund
John G. Freund(exited)
Mission Bay Capital
Mission Bay Capital(exited)
NEA
NEA(exited)
OrbiMed
OrbiMed(exited)
Stephen Hoffman
Stephen Hoffman(exited)
SV Health Investors
SV Health Investors(exited)
Vida Ventures
Vida Ventures(exited)
Sofinnova
Sofinnova(exited)
Gilead Sciences
Gilead Sciences(exited)
MBC Biolabs
MBC Biolabs(exited)
Mission BioCapital
Mission BioCapital(exited)
Ikena Oncology
Ikena Oncology
University of Toronto
University of Toronto(exited)

Related Content

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo